目的:观察体腔循环灌注热化疗治疗晚期肿瘤合并腹腔积液的疗效和安全性。方法随机抽样选取122例经组织病理学或细胞学检查确诊晚期肿瘤伴恶性腹腔积液患者作为研究对象,分别接受体腔循环灌注热化疗及腹腔灌注化疗。观察两组患者的疗效、不良反应及生存时间。结果体腔循环灌注热化疗组与腹腔灌注化疗组的腹腔积液有效率分别为81.1%、55.6%,疾病控制率分别为94.9%、77.8%。两组差异有统计学意义(P<0.05)。两组患者中位PFS分别为6.6、5.4个月,有统计学意义(P<0.001),中位OS分别为15、13个月,无统计学意义(P>0.05);两组不良反应对照无差异(P>0.05)。结论体腔循环灌注热化疗能明显提高晚期肿瘤恶性腹腔积液的近期控制率,疗效显著,不良反应轻。
ObjectiveTo evaluate the effect and safety of body cavity perfusion hyperthermic chemotherapy in the treatment of malignant seroperitoneum. Methods 122 randomly selected patients of malignant seroperitoneum, which were diagnosed by histopathology or cytology, were treated by body cavity perfusion hyperthermic chemotherapy and abdominal perfusion chemotherapy. The efifcacy, adverse reactions and survival time after both treatments were analyzed.Results Body cavity perfusion thermo-chemotherapy group and intraperitoneal chemotherapy for peritoneal effusion efifciency of 81.1% and 55.6%, disease control rate was 94.9% and 77.8%. The difference was statistically signiifcant(P<0.05). Two groups of patients median PFS was 6.6 months and 5.4 months, statistically significant(P<0.001), median OS was 15 months and 13 months, no significant difference(P>0.05); Two adverse reactions in control no difference(P>0.05).Conclusion Thermochemotherapy in systemic circulation showed higher short-term efficiency and better safety than abdominal perfusion chemotherapy in the treatment of malignant seroperitoneum.